EGFR and non-small cell lung carcinoma: In the current study, we show that longitudinal monitoring using plasma-derived cfDNA may be used to detect EGFR sensitizing mutations and monitor the emergence of EGFR resistance mutations in patients with a confirmed histological diagnosis of NSCLC.